Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Accured Expenses (2018 - 2025)

Bicycle Therapeutics' Change in Accured Expenses history spans 8 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 46.61% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $4.1 million, down 57.8%, while the annual FY2025 figure was $4.1 million, 57.8% down from the prior year.
  • Change in Accured Expenses reached $2.0 million in Q4 2025 per BCYC's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $11.5 million in Q2 2023 to a low of -$8.2 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $1.5 million, with a median of $1.5 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: crashed 300.43% in 2021, then skyrocketed 2687.8% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $1.7 million in 2021, then soared by 302.52% to $6.9 million in 2022, then crashed by 153.68% to -$3.7 million in 2023, then surged by 201.63% to $3.7 million in 2024, then tumbled by 46.61% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Change in Accured Expenses are $2.0 million (Q4 2025), $1.1 million (Q3 2025), and $9.2 million (Q2 2025).